Last reviewed · How we verify
Afuresertib ECT - Fed State — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Afuresertib ECT - Fed State (Afuresertib ECT - Fed State) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Afuresertib ECT - Fed State TARGET | Afuresertib ECT - Fed State | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Afuresertib ECT - Fed State CI watch — RSS
- Afuresertib ECT - Fed State CI watch — Atom
- Afuresertib ECT - Fed State CI watch — JSON
- Afuresertib ECT - Fed State alone — RSS
Cite this brief
Drug Landscape (2026). Afuresertib ECT - Fed State — Competitive Intelligence Brief. https://druglandscape.com/ci/afuresertib-ect-fed-state. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab